Dergiler / Turkish Journal of Endocrinology and Metabolism / 2018 / Cilt: 22 - Sayı: 3

Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

Tip 2 Diyabet Tedavisinde Bifazik İnsülin Aspart 30 Kullanımı: Uzman Paneli Görüşleri

Sayfa
183–197
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this statement, expert panel opinions on (a) Recommendations for the appropriate initiation, titration, and intensification of insulin treatment, and (b) The treatment algorithms in initiation, titration, and intensification of biphasic insulin aspart 30 treatment and special conditions specific to changing treatment regimen are presented.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin insufficiency and/or insulin resistance, delay beta cell damage/depletion, and prevent other metabolic co-morbidities and complications.
📊
Temel Bulgular & Veri:In the current treatment algorithms, lifestyle changes (medical nutrition therapy, physical exercise) and oral anti-diabetics are followed by insulin therapy, which is considered a replacement therapy for Type 2 diabetes.
💡
Sonuç & Katkı:In this statement, expert panel opinions on (a) Recommendations for the appropriate initiation, titration, and intensification of insulin treatment, and (b) The treatment algorithms in initiation, titration, and intensification of biphasic insulin aspart 30 treatment and special conditions specific to changing treatment regimen are presented.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin insufficiency and/or insulin resistance, delay beta cell damage/depletion, and prevent other metabolic co-morbidities and complications. In the current treatment algorithms, lifestyle changes (medical nutrition therapy, physical exercise) and oral anti-diabetics are followed by insulin therapy, which is considered a replacement therapy for Type 2 diabetes. Pre-mixed insulin preparations, which are an option for patients with poor blood glucose level control under oral anti-diabetics treatment, have been developed to meet both basal and prandial insulin needs by simulating the physiological changes in insulin levels. The consensus on the necessity of individualizing insulin therapy requires physicians to have a detailed knowledge of the various uses of insulin. Therefore, this comprehensive consensus statement has been prepared by a panel of expert endocrinologists from different regions of Turkey to help physicians use biphasic insulin aspart 30 in suitable patients at the right time. In this statement, expert panel opinions on (a) Recommendations for the appropriate initiation, titration, and intensification of insulin treatment, and (b) The treatment algorithms in initiation, titration, and intensification of biphasic insulin aspart 30 treatment and special conditions specific to changing treatment regimen are presented.

Abstract

Tip 2 diyabet (T2D) tedavisinde amaç, insülinin yetersiz salgısı ve/veya insülin direnci sonucu oluşan hiperglisemiyi ortadan kaldırmak, beta hücre harabiyetini/tükenişini yavaşlatmak, eşlik eden diğer metabolik sorunları düzeltmek ve komplikasyonları önlemektir. Güncel tedavi algoritmalarında yaşam tarzı değişikliği (tıbbi beslenme tedavisi, egzersiz) ve oral antidiyabetikler ile tedavi seçeneklerini izleyen aşamada yer alan insülin, T2D için bir yerine koyma tedavisi olarak değerlendirilmektedir. Hazır karışım insülinler, oral antidiyabetikler ile kan glukoz düzeyleri kontrol altına alınamayan hastaların tedavisinde yer alması önerilen tedavi seçeneklerinden olup, hem bazal hem de prandiyal insülin ihtiyacını fizyolojiye yakın biçimde karşılamak amacıyla geliştirilmişlerdir. İnsülin tedavisinin kişiye özel olması gerektiği konusundaki konsensüs, hekimlerin değişik insülinlerin kullanımları ile ilgili daha ayrıntılı bilgiye sahip olmalarını gerektirmektedir. Bu nedenle, ülkemiz koşullarında bifazik insülin aspart 30’un doğru hastada, doğru zamanda ve doğru biçimde kullanılmasını kolaylaştırmak ve hekimlere yardımcı olmak için Türkiye’nin farklı bölgelerinde görev yapmakta olan deneyimli endokrinologlardan oluşan bir uzman paneli tarafından, bu kapsamlı uzlaşı metni hazırlanmıştır. Bu uzlaşı metninde, uzman paneli görüşleri; a) İnsülin tedavisine uygun başlangıç, titrasyon ve yoğunlaştırma algoritma önerileri ve b) Bifazik insülin aspart 30 tedavisine özgü başlangıç, titrasyon ve yoğunlaştırma tedavi algoritmaları ve tedavi geçişlerine dair özel durumlara ilişkin öneriler temelinde sunulmaktadır.

🔖

Bu Makaleye Atıf Yap

AKALIN, S., AYDIN, H., BALCI, M. K., ÇÖMLEKÇİ, A., DİNÇÇAĞ, N., ERBAŞ, A. T., ERSÖZ, H. Ö., YAVUZ, D. G., GÜLLÜ, S., ŞAHİN, İ., SİVA, Z. O., ÜNLÜHIZARCI, K. (2018). Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations. Turkish Journal of Endocrinology and Metabolism, Cilt: 22 - Sayı: 3, 183–197. https://ajindex.com/articles/370858

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Linjawi S, Sothiratnam R, Sari R, Andersen H, Hiort LC, Rao P. The study of once-and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial. Prim Care Diabetes. 2015;9:370-376.
  2. Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. Prim Care Diabetes. 2014;8:111-117.
  3. Kalra S, Plata-Que T, Kumar D, Mumtaz M, Søndergaad F, Kozlovski P, Bebakar WM. Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs. Diabetes Res Clin Pract. 2010;88:282- 288. Benroubi M. Fear, guilt feelings and misconceptions: barriers to effective insulin treatment in type 2 diabetes. Diabetes Res Clin Pract. 2011;93:S97-99. Kalra S, Ghosal S. Barriers and bridges to insulin therapy: bio psychosocial classification. J Pak Med Assoc. 2017;67:320-321.
  4. Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011;27:1169-1174.
  5. Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM; BIAsp-3021 study group. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:724-732.
  6. Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K. Intensification of insulin therapy with basalbolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2016;51: 417-428.
  7. Kabadi UM, Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract. 2006;72:265-270.
  8. Monnier L, Colette C. Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T trials. Expert Opin Pharmacother. 2008;9:2857-2865.
  9. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30,